Human cytomegalovirus UL18 prevents priming of MHC-E– and MHC-II–restricted CD8 + T cells
Science Immunology · 2024
DOI: 10.1126/sciimmunol.adp5216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Daniel Malouli und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Cytomegalovirus, Macaca mulatta. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Rhesus cytomegalovirus (RhCMV) vectors elicit major histocompatibility complex (MHC)–E–restricted CD8 + T cells that stringently control simian immunodeficiency virus (SIV) in rhesus macaques. These responses require deletion of eight RhCMV chemokine-like open reading frames (ORFs) that are conserved in human cytomegalovirus (HCMV). To determine whether HCMV encodes additional, nonconserved inhibitors of unconventional T cell priming, we inserted 41 HCMV-specific ORFs into a chemokine-deficient strain (68-1 RhCMV). Monitoring of epitope recognition revealed that HCMV UL18 prevented unconventional T cell priming, resulting in MHC-Ia–targeted responses. UL18 is homologous to MHC-I but does not engage T cell receptors and, instead, binds with high affinity to inhibitory leukocyte immunoglobulin-like receptor–1 (LIR-1). UL18 lacking LIR-1 binding no longer interfered with MHC-E–restricted T cell stimulation by RhCMV-infected cells or the induction of unconventionally restricted T cells. Thus, LIR-1 binding needs to be deleted from UL18 of HCMV/HIV vaccines to allow for the induction of protective MHC-E–restricted T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
ORCID-Profile: Daniel Malouli, Mandana Mansouri, Ravi F Iyer, Jason Reed, Courtney Papen, John B Schell, Teresa Beechwood, David Morrow, Roxanne M Gilbride, Kurt Randall, Julia C Ford, Jonah B Sacha, Benjamin N Bimber, Scott G Hansen, Louis J Picker, Klaus Früh
Förderung
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Malouli, D., Taher, H., Mansouri, M., Iyer, R. F., Reed, J., Papen, C., Schell, J. B., Beechwood, T., Martinson, T., Morrow, D., Hughes, C. M., Gilbride, R. M., Randall, K., Ford, J. C., Belica, K., Ojha, S., Sacha, J. B., Bimber, B. N., Hansen, S. G., …, & Früh, K. (2024). Human cytomegalovirus UL18 prevents priming of MHC-E– and MHC-II–restricted CD8 + T cells. Science Immunology. https://doi.org/10.1126/sciimmunol.adp5216
Vancouver
Malouli D, Taher H, Mansouri M, Iyer RF, Reed J, Papen C, et al. Human cytomegalovirus UL18 prevents priming of MHC-E– and MHC-II–restricted CD8 + T cells. Science Immunology. 2024. doi:10.1126/sciimmunol.adp5216
BibTeX
@article{Malouli2024,
author = {Malouli, Daniel and Taher, Husam and Mansouri, Mandana and Iyer, Ravi F and Reed, Jason and Papen, Courtney and Schell, John B and Beechwood, Teresa and Martinson, Thomas and Morrow, David and Hughes, Colette M and Gilbride, Roxanne M and Randall, Kurt and Ford, Julia C and Belica, Karina and Ojha, Sohita and Sacha, Jonah B and Bimber, Benjamin N and Hansen, Scott G and Picker, Louis J and Früh, Klaus},
title = {Human cytomegalovirus UL18 prevents priming of MHC-E– and MHC-II–restricted CD8 + T cells},
journal = {Science Immunology},
year = {2024},
doi = {10.1126/sciimmunol.adp5216}
}
EUVIMED